Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AM3 + SynBalance Metsyn
- Development stage
- Unknown
- Lead developer
- SynBalance
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
AM3 + SynBalance Metsyn is a **combination nutritional supplement** consisting of the immunomodulator **AM3** and the probiotic complex **SynBalance Metsyn**. AM3 is known for its anti-inflammatory and immune-regulatory properties, while SynBalance Metsyn is a blend of multispecies probiotics (*Lactobacillus plantarum PBS067*, *Lactobacillus reuteri PBS072*, *Lactobacillus acidophilus PBS066*) designed to support **metabolic syndrome** through modulation of lipid metabolism, carbohydrate absorption, reduction of systemic and intestinal inflammation, and enhancement of antioxidant defenses. Clinical trials and preclinical studies have shown improvements in metabolic and inflammatory markers, lipid profiles, glycemic control, and a reduction in chronic pathology in subjects with metabolic syndrome. The combination targets inflammatory and metabolic mediators, aiming to minimize risk factors associated with metabolic syndrome and support vascular health[1][2][3][5].
- Other names
- SynBÆctive MetSyn
02
Targets
IL-4 (Interleukin 4)Misfolded SOD1NeuraminidaseGPX4 (Glutathione peroxidase 4)PNLIP (Pancreatic triacylglycerol lipase)TNFA (Tumor necrosis factor alpha (soluble))LCT (Lactase-phlorizin hydrolase)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on AM3 + SynBalance Metsyn.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AM3 + SynBalance Metsyn.